Darlene Dobkowski - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Darlene Dobkowski's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Darlene Dobkowski
Verified
Associate Editorial Director, CURE Magazine
New Jersey
Beats
Health , Human Interest , Mental Health
Yoga pants.
Content
By Darlene Dobkowski Verified| OncLive Verified Enfortumab vedotin (Padcev) demonstrated a manageable safety profile and no unexpected toxicities in patients aged 80 years and older with urothelial carcinoma, according to findings from a real-word study presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium. More patients aged 85 years and older received upfront Padcev dose reduction. There were fewer grade 2/3 (moderate to severe) treatment-related side effects with lower starting doses of Padcev.
By Darlene Dobkowski Verified, Alex Biese Verified| CURE Magazine Verified As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research. This optimism comes in the wake of the Food and Drug Administration’s (FDA’s) approval of Imdelltra (tarlatamab-dlle) in May 2024 for the treatment of patients with extensive-stage small cell lung cancer (SCLC).
By Darlene Dobkowski Verified| OncLive Verified Enfortumab vedotin (Padcev) demonstrated a manageable safety profile and no unexpected toxicities in patients aged 80 years and older with urothelial carcinoma, according to findings from a real-word study presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium. More patients aged 85 years and older received upfront Padcev dose reduction. There were fewer grade 2/3 (moderate to severe) treatment-related side effects with lower starting doses of Padcev.
Company Info
CURE Magazine
Curetoday.com and CURE magazine, our free publication, are the leading resources for patients with cancer, survivors and their caregivers to become empowered advocates in their journeys. We deliver cancer updates, research and education to help make cancer understandable during every stage of the experience and connect the cancer community.
'+1 609-716-7777
Founded: 2002